Akanda’s CanMart Subsidiary to Distribute Award-Winning Cannim Cannabis Products to UK Patients
November 16th, 2021
CanMart has entered a distribution agreement for Cannim’s award-winning medical cannabis products to be available to patients across Britain
LONDON–(BUSINESS WIRE)–Akanda Corp. (“Akanda” or the “Company”) today announced that its wholly-owned subsidiary, CanMart Ltd. (“CanMart”), has entered into a distribution agreement with Australia-based Cannim to bring the award-winning Lumir range of medical cannabis products to UK patients. CanMart will import and distribute Cannim’s full-spectrum medical cannabis oil products over a five-year agreement. Cannim satisfies the Australian market with an award-winning Lumir CBD50 which was recently recognised as CBD Product of the Year at the Australian Cannabis Industry Awards.
“Patients in the UK will now have access to Cannim’s high-quality Jamaica-grown medical cannabis products for the first time,” said Tej Virk, CEO and Director of Akanda. “This is another step in our effort to establish an international supply chain based on a unique ‘open marketplace’ model that provides patients with maximum choice. By bringing together the best third-party products from around the world and combining it with our own high-quality products cultivated at our Bophelo campus in Lesotho from DNA Genetics, we are democratizing access to medical cannabis.”
Added Stuart Marsh, Cannim’s Chief Commercial Officer, “The UK is an important link in a string of new market entries obtained by Cannim in recent months, including securing access to the burgeoning German medicinal cannabis market in August launching into Australia under the Hummingbud brand in September. Thanks to our partnership with CanMart, we are pleased to add the UK to that footprint. We have been impressed by CanMart’s deep expertise and knowledge of the UK market, which has been instrumental in securing the relevant approvals to introduce British patients to our products.”
About Akanda Corp.
Akanda is an international medical cannabis company seeking to help patients around the world lead better lives by democratizing access to cannabis-based medicine and wellness products. Akanda’s initial portfolio includes Bophelo Bioscience & Wellness, a GACP qualified cultivation and processing campus in the Kingdom of Lesotho in Southern Africa focused on cultivating ethically sourced cannabis of the highest quality at a low-cost compared to many of its competitors, and CanMart, a UK-based fully approved pharmaceutical importer and distributor which supplies pharmacies and clinics within the U.K.
A cornerstone of Akanda’s value system is its fundamental commitment to using its operations as a force for sustainability and social good. Akanda will seek to deliver on this promise by driving positive change in wellness, empowering individuals in Lesotho, and by uplifting the quality of the lives of employees and the local communities where it operates – while limiting its carbon footprint. Adhering to best practice ESG operating and disclosure standards is among Akanda’s highest priorities.
Connect with Akanda: Email | Website | LinkedIn | Twitter | Instagram
Established in 2017, Cannim was founded on the vision of moving cannabis from the darkness into the light© and helping bring the benefits of medicinal cannabis to the world. Since that time, Cannim has invested in farms, GMP production facilities and initiating research in Jamaica and Australia utilizing expertise for these activities from Israel, Jamaica, the U.S., UK and Australia. It operates with an international network of EU GMP (Good Manufacturing Practice) manufacturers and channels to market.
Cannim’s circular integrated business is built on three key pillars of Safety, Science and Scale©, and is focused on delivering premium quality products, consistently and reliably to patients globally. This long-term vision is integral to Cannim’s approach to improving its consumers’ health and wellness, delivering ‘Better Balanced Bodies’© and establishing world-leading medicinal and wellness cannabis brands.
Matt Chesler, CFA
Allison + Partners
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.